MiNK Therapeutics (INKT) Set to Release Quarterly Earnings on Wednesday

MiNK Therapeutics (NASDAQ:INKT) is projected to announce its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect MiNK Therapeutics to announce earnings of ($0.66) per share and revenue of $0.07 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 8:30 AM ET.

MiNK Therapeutics (NASDAQ:INKT) last posted its earnings results on Thursday, August 13th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.02). On average, analysts expect MiNK Therapeutics to post ($2.53) EPS for the current fiscal year and ($2.41) EPS for the next fiscal year.

MiNK Therapeutics Trading Up 1.2%

Shares of INKT stock opened at $10.47 on Monday. The firm has a market capitalization of $53.42 million, a price-to-earnings ratio of -4.36 and a beta of 0.49. The business’s 50-day moving average price is $11.23 and its 200-day moving average price is $11.26. MiNK Therapeutics has a 12 month low of $8.48 and a 12 month high of $16.93.

Insider Buying and Selling

In other MiNK Therapeutics news, CEO Jennifer Buell sold 6,938 shares of the company’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $10.56, for a total value of $73,265.28. Following the sale, the chief executive officer owned 74,195 shares in the company, valued at approximately $783,499.20. The trade was a 8.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 20.40% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on INKT shares. HC Wainwright assumed coverage on shares of MiNK Therapeutics in a research report on Wednesday, November 4th. They set a “buy” rating and a $38.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Friday, October 2nd. B. Riley Financial restated a “buy” rating and issued a $50.00 price target (up from $43.00) on shares of MiNK Therapeutics in a research report on Wednesday, October 21st. Finally, Zacks Research downgraded shares of MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $44.00.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses.

MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.